Final Analysis: Phase II Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Key Findings
We studied the effectiveness and safety of a 24-cycle treatment combining Daratumumab with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients without needing a stem cell transplant.
Our primary goal was to achieve a stringent complete response (sCR) and/or measurable residual disease (MRD) less than 10-5 after the 8th treatment cycle.
Results showed a 75% rate of sCR and/or MRD less than 10-5, meeting our effectiveness target. The percentage of patients achieving a 10-6 MRD negative rate improved with continued treatment beyond the 8th cycle.
Additionally, our estimated 3-year progression-free survival rate was 85%, with a 3-year overall survival rate of 95%.
Side effects primarily included upper respiratory infections, with 7% of cases classified as grade 3-4, and no treatment-related deaths occurred.
Practical Solutions
Clinical trials play a crucial role in developing safe and effective treatments. It’s essential to translate these benefits into everyday medical practice. Our AI-driven platform, DocSym, consolidates clinical protocols and research into a single, easily accessible knowledge base for healthcare professionals.
In today’s healthcare landscape, efficient operations are vital. Our mobile apps support scheduling, treatment monitoring, and telemedicine, enabling easier management of patient care and digital expansion of services.
By leveraging AI, clinics can enhance workflows, improve patient outcomes, and reduce paper-based routines. Find out more about how our solutions can support medical practices at aidevmd.com.
